Reoviridae vaccine
AssigneeLondon School of Hygiene and Tropical Medicine
InventorPolly Roy
Life of this patent
Estimating the term…
Abstract
The invention relates to an isolated African horse sickness virus (AHSV) ssRNA comprising a plurality of mutations; a complementary cell for replication of a vaccinal viral strain from said ssRNA; a vaccinal viral strain derived from said ssRNA; use of said vaccinal viral strain and/or isolated ssRNA in the vaccination of an animal against an infection by AHSV; a method of vaccination comprising same; and a pharmaceutical composition comprising said vaccinal viral strain and/or said isolated ssRNA.
Claims23
An isolated viral ssRNA comprising at least a part of an S9 segment from an African Horse Sickness Virus (AHSV) genome, wherein the at least a part of the S9 segment comprises a plurality of mutations, each mutation providing or encoding a stop codon that destroys a function of at least one essential gene while retaining a length of the S9 segment.
A kit comprising:
- an isolated viral ssRNA comprising at least a part of an S9 segment from an African Horse Sickness Virus (AHSV) genome, wherein the at least a part of the S9 segment comprises a plurality of mutations, each mutation providing or encoding a stop codon that destroys a function of at least one essential gene while retaining a length of the S9 segment;
- and
- a cell expressing at least one essential gene of the at least a part of S9 segment from AHSV that complements said at least one essential gene mutated in the ssRNA, which thereby enables replication of a vaccinal viral strain in the cell.
A method for generating defective AHSV virus of a given serotype, comprising:
- a) introducing a plurality of mutations in an S9 segment of said virus while retaining a length of the S9 segment, each mutation providing or encoding a stop codon that destroys a function of at least one essential gene;
- and
- b) reassorting or exchanging the following selected segments S2+S6;
- S2+S6+S7;
- S2+S6+S7+S3;
- or S2+S6+S7+S3+S10 to generate the following serotypes def-AHSV8 and def-AHSV9 serotypes;
- def-AHSV3 and def-AHSV4;
- def-AHSV5, def-AHSV6 and def-AHSV7;
- and def-AHSV2 respectively.
A method for generating defective AHSV virus of a given serotype, comprising:
- a) introducing a plurality of mutations in an S9 segment of said virus while retaining a length of the S9 segment, each mutation providing or encoding a stop codon;
- and
- b) reassorting or exchanging the following selected segments to generate the following serotypes:
- the reassortment of two segments (S2+S6) encoding outer shell proteins VP2 and VP5 to generate def-AHSV8 and def-AHSV9 serotypes;
- and/or
- the reassortment of the two segments (S2+S6) encoding outer shell proteins VP2 and VP5 and the segment (S7) encoding middle-core protein VP7 to generate def-AHSV3 and def-AHSV4;
- and/or
- the reassortment of the two segments (S2+S6) encoding outer shell proteins VP2 and VP5 and the segment (S7) encoding middle-core protein VP7 and the segment (S3) encoding middle-core protein VP3 to generate def-AHSV5, def-AHSV6 and def-AHSV7;
- and/or
- the reassortment of the two segments (S2+S6) encoding outer shell proteins VP2 and VP5 and the segment (S7) encoding middle-core protein VP7 and the segment (S3) encoding middle-core protein VP3 and the segment (S10) encoding NS3/NS3A to generate def-AHSV2.
Dependencies are inferred from the claim text.